Dynamin 2 interacts with α-actinin 4 to drive tumor cell invasion.


Journal

Molecular biology of the cell
ISSN: 1939-4586
Titre abrégé: Mol Biol Cell
Pays: United States
ID NLM: 9201390

Informations de publication

Date de publication:
15 03 2020
Historique:
pubmed: 23 1 2020
medline: 23 1 2021
entrez: 23 1 2020
Statut: ppublish

Résumé

The large GTPase Dynamin 2 (Dyn2) is known to increase the invasiveness of pancreatic cancer tumor cells, but the mechanisms by which Dyn2 regulates changes in the actin cytoskeleton to drive cell migration are still unclear. Here we report that a direct interaction between Dyn2 and the actin-bundling protein alpha-actinin (α-actinin) 4 is critical for tumor cell migration and remodeling of the extracellular matrix in pancreatic ductal adenocarcinoma (PDAC) cells. The direct interaction is mediated through the C-terminal tails of both Dyn2 and α-actinin 4, and these proteins interact at invasive structures at the plasma membrane. While Dyn2 binds directly to both α-actinin 1 and α-actinin 4, only the interaction with α-actinin 4 is required to promote tumor cell invasion. Specific disruption of the Dyn2-α-actinin 4 interaction blocks the ability of PDAC cells to migrate in either two dimensions or invade through extracellular matrix as a result of impaired invadopodia stability. Analysis of human PDAC tumor tissue additionally reveals that elevated α-actinin 4 or Dyn2 expression are predictive of poor survival. Overall, these data demonstrate that Dyn2 regulates cytoskeletal dynamics, in part, by interacting with the actin-binding protein α-actinin 4 during tumor cell invasion.

Identifiants

pubmed: 31967944
doi: 10.1091/mbc.E19-07-0395
pmc: PMC7185896
doi:

Substances chimiques

ACTN4 protein, human 0
Actinin 11003-00-2
Dynamin II EC 3.6.5.5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

439-451

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK084567
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA102701
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA104125
Pays : United States

Références

Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
J Cell Sci. 2000 Jun;113 ( Pt 11):1993-2002
pubmed: 10806110
J Biol Chem. 2009 Sep 4;284(36):23995-4005
pubmed: 19605363
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Biochem Biophys Res Commun. 2016 Nov 18;480(3):409-414
pubmed: 27771248
J Cell Biol. 2000 Oct 2;151(1):187-98
pubmed: 11018064
Clin Cancer Res. 2008 Sep 1;14(17):5348-56
pubmed: 18765526
Mol Biol Cell. 2003 Mar;14(3):1074-84
pubmed: 12631724
Oncotarget. 2013 Feb;4(2):362-72
pubmed: 23482348
Oncogene. 2012 Mar 8;31(10):1228-41
pubmed: 21841817
J Cell Biol. 1995 Jul;130(1):67-77
pubmed: 7790378
Cancer Med. 2014 Feb;3(1):14-24
pubmed: 24402972
Sci Rep. 2016 Jun 07;6:27383
pubmed: 27272015
Biochem J. 2014 Apr 1;459(1):1-13
pubmed: 24627985
PLoS One. 2013 Dec 09;8(12):e77956
pubmed: 24348990
Cell Biosci. 2015 Aug 18;5:41
pubmed: 26288717
Methods Mol Biol. 2013;1046:343-57
pubmed: 23868599
J Neurochem. 2011 Apr;117(1):48-60
pubmed: 21210813
Biochem J. 2013 Jun 15;452(3):477-88
pubmed: 23557398
EMBO J. 1998 Aug 3;17(15):4346-57
pubmed: 9687503
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
Annu Rev Cell Dev Biol. 2000;16:483-519
pubmed: 11031245
Cell Biosci. 2015 Aug 25;5:49
pubmed: 26312134
J Cell Sci. 2006 May 1;119(Pt 9):1683-90
pubmed: 16636070
Curr Biol. 2005 Jul 26;15(14):1276-85
pubmed: 16051170
Cell Mol Life Sci. 2008 Sep;65(17):2688-701
pubmed: 18488141
Nat Rev Mol Cell Biol. 2012 Jan 11;13(2):75-88
pubmed: 22233676
J Biol Chem. 2011 Jan 21;286(3):1850-9
pubmed: 21078666
EMBO J. 2010 Nov 3;29(21):3593-606
pubmed: 20935625
J Cell Biol. 2019 May 6;218(5):1670-1685
pubmed: 30894403
Br J Cancer. 2015 Feb 17;112(4):704-13
pubmed: 25602965
Mol Cell Biol. 2003 Mar;23(6):2162-70
pubmed: 12612086
PLoS One. 2015 Apr 10;10(4):e0120616
pubmed: 25860875
PLoS One. 2014 Apr 07;9(4):e94330
pubmed: 24710573
J Biol Chem. 2014 Nov 21;289(47):32717-28
pubmed: 25296750
Mol Cell Proteomics. 2007 Mar;6(3):479-91
pubmed: 17151021
Mol Biol Cell. 2011 May;22(9):1529-38
pubmed: 21411625
Cancer Res. 2019 Jun 1;79(11):2878-2891
pubmed: 30975647
Cancer Res. 2006 Mar 15;66(6):3034-43
pubmed: 16540652
Mol Biol Cell. 1998 Sep;9(9):2595-609
pubmed: 9725914
Cell Motil Cytoskeleton. 2001 Mar;48(3):190-200
pubmed: 11223950
Curr Opin Cell Biol. 2003 Feb;15(1):31-9
pubmed: 12517701
Mol Biol Cell. 2003 Mar;14(3):1085-96
pubmed: 12631725
Pancreas. 2009 Nov;38(8):968-76
pubmed: 19672209
J Cell Biol. 1998 Apr 6;141(1):85-99
pubmed: 9531550
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Int J Oncol. 2016 Sep;49(3):877-86
pubmed: 27572123
Dev Cell. 2013 Mar 25;24(6):573-85
pubmed: 23537630
Eur J Cell Biol. 2017 Oct;96(7):685-694
pubmed: 28797528

Auteurs

Kevin M Burton (KM)

Mayo Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905.

Hong Cao (H)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905.

Jing Chen (J)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905.

Li Qiang (L)

Mayo Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905.
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905.

Eugene W Krueger (EW)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905.

Katherine M Johnson (KM)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905.

William R Bamlet (WR)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905.

Lizhi Zhang (L)

Department of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905.

Mark A McNiven (MA)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905.
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905.

Gina L Razidlo (GL)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905.
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH